Search
Redaporfin
go.drugbank.com/drugs/DB17219InvestigationalSynonyms: 3,3',3'',3'''-(7,8,17,18-tetrahydroporphyrin-5,10,15,20-tetrayl)tetrakis(2,4-difluoro-n-methylbenzenesulfonamide), Benzenesulfonamide, 3,3',3'',3'''-(7,8,17,18-tetrahydro-21h,23h-porphine-5,10,15,20-tetrayl)tetrakis(2,4-difluoro-n-methyl-Categories: P-glycoprotein substratesGI-101
go.drugbank.com/drugs/DB17243InvestigationalGI-101 is a bi-specific fragment crystallizable region (Fc) fusion protein containing a cluster of differentiation 80 ectodomain as an N-terminal moiety and interleukin-2 variant as a C-terminal moiety
P-BCMA-101
go.drugbank.com/drugs/DB17371InvestigationalP-BCMA-101 is an autologous CAR-T therapy developed using Poseida’s piggyBac platform technology.
EGT-201
go.drugbank.com/drugs/DB17648ExperimentalEGT-201 is an adeno-associated viral vector serotype 9 (AAV9) vector-based gene therapy consisting of the alpha-N-acetyglucosaminidase (NAGLU) transgene.
Linafexor
go.drugbank.com/drugs/DB18031InvestigationalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesGunagratinib
go.drugbank.com/drugs/DB18191ExperimentalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesNerandomilast
go.drugbank.com/drugs/DB18237ApprovedInvestigationalNerandomilast is a phosphodiesterase 4 (PDE4) inhibitor that preferentially inhibits the PDE4B subtype. It has one chiral center and is the R-stereoisomer. On October 7, 2025, nerandomilast was approved as the first new treatment for idi...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsHeparan-N-sulfatase (human, recombinant)
go.drugbank.com/drugs/DB18483InvestigationalRecombinant human heparan-N-sulfatase (rhHNS) is under investigation for the treatment mucopolysaccharidosis type IIIA.
Synonyms: Recombinant human heparan-N-sulfatase, Heparan-N-sulfatase (human, recombinant)ACTX-401
go.drugbank.com/drugs/DB18504ExperimentalACTX-401 is a single-stranded, non-replicating recombinant adeno-associated viral vector serotype 9 containing the human immunoglobulin u-binding protein 2 cDNA.
Elzasonan
go.drugbank.com/drugs/DB18969InvestigationalElzasonan is under investigation in clinical trial NCT00275197 (A Research Study to Compare the Treatments of a Combination of Elzasonan With Zoloft, to Zoloft Alone, or Placebo in People With Major Depressive Disorder (MDD)).
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 Substrates